The congenital hyperinsulinism market is poised for steady growth, driven by increasing disease awareness, improved neonatal screening, and advances in genetic and molecular diagnostics. Growth is further supported by the continued need for effective therapies, as existing treatment options such as diazoxide and somatostatin analogs remain inadequate for many patients. 先天性高胰岛素血症市场有望实现稳步增长，这得益于疾病认知度的提高、新生儿筛查的改善以及遗传和分子诊断技术的进步。由于地塞米松和生长抑素类似物等现有治疗方案对许多患者而言仍显不足，对有效疗法的持续需求也进一步推动了市场增长。Meanwhile, emerging targeted therapies such as Dasiglucagon (Zealand Pharma), Ersodetug (RZ358; Rezolute), Avexitide (Amylyx Pharmaceuticals), Efpegerglucagon (HM15136; Hanmi Pharmaceutical), and others are expected to diversify the treatment landscape and create new commercial opportunities.. 与此同时，达西格列酮（Zealand Pharma）、Ersodetug（RZ358；Rezolute）、阿维西肽（Amylyx Pharmaceuticals）、Efpegerglucagon（HM15136；韩美制药）等新兴靶向疗法有望使治疗格局多样化，并创造新的商业机会。LAS VEGAS 拉斯维加斯, ，Aug. 26, 2026 2026年8月26日/PRNewswire/ -- Recently published Congenital Hyperinsulinism Market Insights report includes a comprehensive understanding of current treatment practices, congenital hyperinsulinismemerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].. /美通社/ -- 最近发布的《先天性高胰岛素血症市场洞察》报告全面分析了当前的治疗实践、先天性高胰岛素血症新兴药物、各疗法的市场份额，以及2022年至2036年的当前和预测市场规模，并按主要市场（美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）进行了细分。Congenital Hyperinsulinism Market Summary 先天性高胰岛素血症市场概览The market size for congenital hyperinsulinismwas found to be 先天性高胰岛素血症的市场规模被发现为USD 110 million 1.1亿美元in the 7MM in 2025. 在2025年的7MM中。The United States accounted for the largest congenital hyperinsulinismtreatment market size, approximately 美国占据了最大的先天性高胰岛素血症治疗市场规模，约占41% 41%of the total market size in the 7MM in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. 占2025年七大主要市场（7MM）总市场规模的比例，并与包括欧盟四国（德国、法国、意大利和西班牙）、英国和日本在内的其他主要市场进行比较。The total diagnosed prevalent cases of congenital hyperinsulinism in the 7MM were 在7MM中，先天性高胰岛素血症的总确诊患病病例数为15,700 15,700cases in 2025, which is expected to increase during the forecast period (2026–2036). 2025年的病例数，预计在预测期（2026–2036年）内将有所增加。Leading congenital hyperinsulinism companies, such as 先天性高胰岛素血症领域的领先企业，例如Zealand Pharma, Rezolute, Amylyx Pharmaceuticals, Hanmi Pharmaceutical, Zealand Pharma、Rezolute、Amylyx Pharmaceuticals、韩美制药，and others, are developing new congenital hyperinsulinism treatmentdrugs that can be available in the congenital hyperinsulinism market in the coming years. 以及其他公司，正在开发新的先天性高胰岛素血症治疗药物，这些药物有望在未来几年内进入先天性高胰岛素血症市场。The promising congenital hyperinsulinism therapies in clinical trials include 临床试验中前景良好的先天性高胰岛素血症疗法包括Dasiglucagon, Ersodetug (RZ358), Avexitide, Efpegerglucagon (HM15136), 达西格卢糖，Ersodetug（RZ358），Avexitide，Efpegerglucagon（HM15136），and others. 等等。Discover new treatment for congenital hyperinsulinism @ 发现先天性高胰岛素血症的新疗法 @https://www.delveinsight.com/report-store/congenital-hyperinsulinism-market https://www.delveinsight.com/report-store/congenital-hyperinsulinism-marketKey Factors Driving the Growth of the Congenital Hyperinsulinism Market 推动先天性高胰岛素血症市场增长的关键因素Rising Disease Awareness and Improved Diagnosis: 疾病认知度提升与诊断水平改善：Growing awareness of congenital hyperinsulinism (CHI) among clinicians and caregivers is supporting earlier recognition and diagnosis. Advances in genetic testing and molecular diagnostics are also enabling more accurate identification of disease subtypes. 临床医生和照护者对先天性高胰岛素血症（CHI）的认识不断提高，有助于更早地识别和诊断该病。基因检测和分子诊断技术的进步也使得疾病亚型的鉴定更加准确。Advancements in Genetic and Molecular Research: 遗传与分子研究的进展：Improved understanding of the genetic mechanisms underlying CHI is facilitating the development of targeted therapeutic strategies. Growing knowledge of mutations affecting insulin secretion may also support more personalized approaches to treatment. 对先天性高胰岛素血症（CHI）潜在遗传机制的深入理解，正在推动靶向治疗策略的开发。对影响胰岛素分泌突变的日益了解，也有助于实现更加个体化的治疗方案。Increasing Detection of Rare Genetic Disorders: 罕见遗传病检出率不断上升：Although congenital hyperinsulinism is a rare disorder, advancements in diagnostic techniques, patient registries, and disease reporting mechanisms are improving case identification worldwide. The growing number of diagnosed patients is, in turn, driving continued demand for effective treatment options.. 尽管先天性高胰岛素血症是一种罕见疾病，但诊断技术、患者登记系统以及疾病报告机制的进步正在改善全球范围内的病例识别。确诊患者数量的增加反过来又推动了对有效治疗方案的持续需求。Growing Pipeline of Novel Therapies: 不断增长的 novel 疗法管线：Increasing clinical research into innovative pharmacological and molecular approaches is expected to expand treatment options for patients with congenital hyperinsulinism. The emergence of therapies such as 预计对创新药理学和分子方法的临床研究不断增加，将为先天性高胰岛素血症患者扩大治疗选择。诸如以下疗法的出现Dasiglucagon 达西格卢卡肽(Zealand Pharma), （Zealand Pharma）Ersodetug 埃尔斯多图格(RZ358; Rezolute), (RZ358；Rezolute)Avexitide 阿维西肽(Amylyx Pharmaceuticals), （Amylyx Pharmaceuticals）Efpegerglucagon 依佩格胰高血糖素(HM15136; Hanmi Pharmaceutical), and others targeting the underlying mechanisms of inappropriate insulin secretion could significantly reshape the market. （HM15136；韩美制药），以及其他针对胰岛素分泌失调潜在机制的药物，可能会显著重塑市场格局。Download the report to understand the top emerging congenital hyperinsulinism drugs@ 下载报告以了解新兴的先天性高胰岛素血症主要药物Congenital Hyperinsulinism Clinical Trials 先天性高胰岛素血症临床试验As per Aparna Thakur, Project Manager of Forecasting at DelveInsight, novel strategies, including gene-based and other mechanism-driven interventions, are being explored to correct or modulate the underlying defects in insulin regulation. Although still in early stages, these therapies hold potential for disease-modifying outcomes but face challenges related to clinical validation, long-term efficacy, and safety.. 据DelveInsight预测项目经理Aparna Thakur表示，人们正在探索包括基因疗法和其他机制驱动干预在内的新型策略，以纠正或调节胰岛素调节中的根本缺陷。尽管这些疗法仍处于早期阶段，但它们具有改变疾病进程的潜力，但也面临着与临床验证、长期疗效和安全性相关的挑战。DelveInsight's Congenital Hyperinsulinism Market Report delivers executive-level intelligence on the evolving market landscape, integrating epidemiology, treatment practices, competitive dynamics, emerging therapies, and market forecasts across the major markets through 2036. Built on a rigorous methodology combining comprehensive secondary research, primary interviews with key opinion leaders and industry experts, and proprietary patient-based forecasting models, the report provides a reliable foundation for strategic planning. DelveInsight 的《先天性高胰岛素血症市场报告》提供关于不断演变的市场格局的高层战略情报，整合了主要市场直至 2036 年的流行病学、治疗实践、竞争动态、新兴疗法及市场预测。该报告基于严谨的方法论构建，结合了全面的二手研究、与关键意见领袖和行业专家的一手访谈，以及专有的基于患者的预测模型，为战略规划提供了可靠的基础。Designed for pharmaceutical and biotech executives, it enables informed decisions on portfolio strategy, business development, market entry, investment prioritization, and commercial planning.. 专为制药和生物技术高管设计，助力其在产品组合战略、业务发展、市场准入、投资优先级排序以及商业规划方面做出明智决策。Congenital Hyperinsulinism Market Analysis 先天性高胰岛素血症市场分析The treatment landscape for congenital hyperinsulinism remains primarily centered on symptom control and the prevention of hypoglycemic episodes. 先天性高胰岛素血症的治疗格局仍主要以控制症状和预防低血糖发作为中心。Current management strategies include frequent feeding, continuous glucose administration, and pharmacological therapy. 当前的管理策略包括频繁喂养、持续葡萄糖给药以及药物治疗。Diazoxide 二氮嗪is generally considered the first-line treatment, while somatostatin analogs may be used in patients who do not respond adequately. In severe cases, particularly those involving focal disease, surgical approaches such as partial pancreatectomy may be necessary. 通常被视为一线治疗，而对于反应不足的患者，可以使用生长抑素类似物。在严重病例中，尤其是涉及局灶性病变的情况下，可能需要采用手术方法，如部分胰腺切除术。However, treatment outcomes remain inconsistent, with many patients showing inadequate responses or resistance to established therapies. 然而，治疗结果仍然不一致，许多患者对现有疗法反应不足或产生耐药性。This persistent variability underscores the substantial unmet need for more effective and durable treatment options, particularly therapies capable of addressing the underlying pathophysiology rather than merely managing hypoglycemic symptoms. 这种持续存在的变异性凸显出对更有效且更持久的治疗方案的巨大未满足需求，尤其是那些能够解决潜在病理生理机制而不仅仅是控制低血糖症状的疗法。The therapeutic landscape is gradually shifting toward targeted, mechanism-based approaches. Among the notable investigational therapies is 治疗格局正逐渐向靶向、基于机制的方法转变。其中值得关注的在研疗法包括Ersodetug (RZ358) 埃索德图格（RZ358）, which is designed to modulate insulin receptor signaling and represents a novel therapeutic strategy for patients with severe or treatment-resistant congenital hyperinsulinism. Such approaches could mark a transition from conventional symptom management toward functional disease modification. ，其旨在调节胰岛素受体信号传导，并为重度或难治性先天性高胰岛素血症患者代表了一种新型治疗策略。此类方法可能标志着从传统的症状管理向功能性疾病修饰的转变。Pharmaceutical companies and research organizations are increasingly investing in the development of novel therapies for this rare disorder. 制药公司和研究机构正日益加大对这种罕见疾病新型疗法开发的投入。Ongoing research is aimed at deepening the understanding of congenital hyperinsulinism biology and identifying new therapeutic targets, with genetic and molecular insights playing an increasingly important role in guiding drug development. 正在进行的研究旨在深化对先天性高胰岛素血症生物学的理解，并识别新的治疗靶点，其中遗传学和分子生物学见解在指导药物开发方面发挥着日益重要的作用。The emerging congenital hyperinsulinism pipeline remains relatively limited but is gaining momentum, with several investigational candidates potentially capable of reshaping the competitive landscape and addressing long-standing treatment gaps. 先天性高胰岛素血症的新兴研发管线仍然相对有限，但正逐渐获得动力，几种在研候选药物有可能重塑竞争格局并解决长期存在的治疗空白。As development programs advance and competition increases, the market is expected to see greater innovation and potentially improved outcomes for patients with this challenging condition. 随着研发项目的推进和竞争的加剧，预计市场将出现更多创新，并为患有这种疑难疾病的患者带来潜在更好的治疗结果。Congenital Hyperinsulinism Competitive Landscape 先天性高胰岛素血症竞争格局Some of the congenital hyperinsulinism drugs under development include 正在研发中的先天性高胰岛素血症药物包括Dasiglucagon 达西格卢卡肽(Zealand Pharma), （Zealand Pharma）Ersodetug 埃索德图格(RZ358; Rezolute), (RZ358；Rezolute)Avexitide 阿维西肽(Amylyx Pharmaceuticals), （Amylyx Pharmaceuticals）Efpegerglucagon 艾芬格胰高血糖素(HM15136; Hanmi Pharmaceutical), and others. (HM15136；韩美制药)，以及其他。Zealand Pharma's ZEGALOGUE Zealand Pharma 的 ZEGALOGUEis a glucagon analog that elevates blood glucose by promoting glucose release from the liver. Although it is approved for the treatment of severe hypoglycemia in patients with diabetes, its mechanism may also offer therapeutic potential in congenital hyperinsulinism by counteracting hypoglycemia caused by excessive insulin secretion. 是一种胰高血糖素类似物，通过促进肝脏释放葡萄糖来升高血糖。尽管它已被批准用于治疗糖尿病患者的严重低血糖症，但其作用机制也可能通过对抗因胰岛素分泌过多引起的低血糖，为先天性高胰岛素血症提供治疗潜力。The drug is currently in the registration stage, with the sponsor planning to resubmit a New Drug Application (NDA) in the second half of 2026.. 该药物目前处于注册阶段，申办方计划在2026年下半年重新提交新药上市申请（NDA）。Rezolute's Ersodetug Rezolute 公司的 Ersodetugis an investigational monoclonal antibody that targets the insulin receptor to modulate insulin activity and help maintain stable blood glucose levels in patients with congenital hyperinsulinism. The therapy is currently being evaluated in Phase III clinical development. It has received multiple regulatory designations, including . 是一种研究性单克隆抗体，靶向胰岛素受体以调节胰岛素活性，帮助先天性高胰岛素血症患者维持稳定的血糖水平。该疗法目前正处于III期临床开发评估阶段。它已获得多项监管认定，包括。Breakthrough Therapy Designation (BTD) 突破性疗法认定（BTD）, the UK's ，英国的Innovative Licensing and Access Pathway (ILAP) designation, and Orphan Drug Designations (ODD) 创新许可和准入途径（ILAP）认定，以及孤儿药资格认定（ODD）from the US and European Union for congenital hyperinsulinism and insulinoma-associated hypoglycemia. However, in December 2025, Rezolute announced that the Phase III sunRIZE study of ersodetug in congenital hyperinsulinism did not achieve its primary endpoint of reducing weekly hypoglycemia events.. 用于美国和欧盟批准的先天性高胰岛素血症及胰岛素瘤相关低血糖症。然而，2025年12月，Rezolute公司宣布，ersodetug治疗先天性高胰岛素血症的III期sunRIZE研究未能达到其主要终点，即减少每周低血糖事件的发生次数。Hanmi Pharmaceutical's Efpegerglucagon 韩美药品的Efpegerglucagonis a long-acting glucagon analog currently being investigated in Phase II clinical development for congenital hyperinsulinism. The therapy is designed to increase blood glucose levels by stimulating hepatic glucose release. It has received 是一种长效胰高血糖素类似物，目前正处于针对先天性高胰岛素血症的II期临床研究阶段。该疗法旨在通过刺激肝脏释放葡萄糖来提高血糖水平。它已获得Orphan Drug Designation 孤儿药认定from both the FDA and EMA, as well as the FDA's 来自美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA），以及美国食品药品监督管理局（FDA）的Rare Pediatric Disease Designation (RPDD) 罕见儿科疾病认定（RPDD）. The global Phase II study is ongoing, with topline results anticipated in the second half of 2026. Earlier interim findings indicated a reduction in hypoglycemia events and demonstrated favorable tolerability. In November 2024, Hanmi presented interim Phase II data for efpegerglucagon in congenital hyperinsulinism at the European Society for Paediatric Endocrinology (ESPE) conference.. 全球II期研究正在进行中，预计将于2026年下半年公布主要结果。早期的中期分析结果显示低血糖事件减少，并表现出良好的耐受性。2024年11月，韩美制药在欧洲儿科内分泌学会（ESPE）会议上公布了efpegerglucagon治疗先天性高胰岛素血症的II期中期数据。The anticipated launch of these emerging therapies are poised to transform the congenital hyperinsulinismmarket landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the congenital hyperinsulinismmarket landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.. 这些新兴疗法的预期上市将在未来几年内改变先天性高胰岛素血症市场的格局。随着这些前沿疗法不断成熟并获得监管批准，预计它们将重塑先天性高胰岛素血症市场格局，提供新的护理标准，并为医疗创新和经济增长带来机遇。Discover more about which pipeline drugs could transform congenital hyperinsulinism treatment market @ 了解更多关于哪些在研药物可能改变先天性高胰岛素血症治疗市场的信息 @Congenital Hyperinsulinism Medications 先天性高胰岛素血症药物Congenital Hyperinsulinism Epidemiology Segmentation 先天性高胰岛素血症流行病学细分The congenital hyperinsulinismepidemiology section provides insights into the historical and current congenital hyperinsulinismpatient pool and forecasted trends for the leading markets. In 2025, the estimated number of diagnosed prevalent cases of congenital hyperinsulinism in the US were around . 先天性高胰岛素血症流行病学部分提供了对历史及当前先天性高胰岛素血症患者群体以及主要市场预测趋势的洞察。2025年，美国估计确诊的先天性高胰岛素血症现患病例数约为。3,500 3,500, and this figure is expected to rise by 2036. ，预计到2036年这一数字还将上升。The congenital hyperinsulinismtreatment market reportproffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into: 先天性高胰岛素血症治疗市场报告提供了2022年至2036年研究期间主要市场的流行病学分析，细分如下：Total Diagnosed Prevalent Cases of Congenital Hyperinsulinism 先天性高胰岛素血症的确诊总患病病例数Type-specific Diagnosed Prevalent Cases of Congenital Hyperinsulinism based on Histological Presentation 基于组织学表现的先天性高胰岛素血症各类型确诊患病病例Mutation-specific Diagnosed Prevalent Cases of Congenital Hyperinsulinism 突变特异性的先天性高胰岛素血症确诊现患病例Total Treated Cases of Congenital Hyperinsulinism 先天性高胰岛素血症的总治疗病例数Congenital Hyperinsulinism Market Report Metrics 先天性高胰岛素血症市场报告指标Details 详情Study Period 学习阶段2022–2036 2022–2036Coverage 覆盖范围7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 7MM [美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本]。Congenital Hyperinsulinism Market CAGR 先天性高胰岛素血症市场复合年增长率12% 12%Congenital Hyperinsulinism Market Size in 2025 2025年先天性高胰岛素血症市场规模USD 110 Million 1.1亿美元Key Congenital Hyperinsulinism Companies 先天性高胰岛素血症的主要企业Zealand Pharma, Rezolute, Amylyx Pharmaceuticals, Hanmi Pharmaceutical, and others Zealand Pharma、Rezolute、Amylyx Pharmaceuticals、韩美制药等KeyCongenital HyperinsulinismTherapies 先天性高胰岛素血症的关键疗法Dasiglucagon, Ersodetug (RZ358), Avexitide, Efpegerglucagon (HM15136), and others 达西格鲁肽、Ersodetug（RZ358）、阿维西肽、Efpegerglucagon（HM15136）及其他Scope of the 范围Congenital Hyperinsulinism 先天性高胰岛素血症Market Report 市场报告Congenital Hyperinsulinism Patient Population Forecast 先天性高胰岛素血症患者人群预测Congenital Hyperinsulinism Therapeutics Market Size 先天性高胰岛素血症治疗药物市场规模Congenital Hyperinsulinism Pipeline Analysis 先天性高胰岛素血症研发管线分析Congenital Hyperinsulinism Market Size and Trends 先天性高胰岛素血症市场规模与趋势Congenital Hyperinsulinism Market Opportunity 先天性高胰岛素血症市场机遇Congenital Hyperinsulinism Market Unmet Needs 先天性高胰岛素血症市场的未满足需求KOL's Views on Congenital Hyperinsulinism 关键意见领袖对先天性高胰岛素血症的观点Congenital Hyperinsulinism Market Access and Reimbursement 先天性高胰岛素血症的市场准入与报销Table of Contents 目录1 1Congenital Hyperinsulinism Market Key Insights 先天性高胰岛素血症市场关键洞察2 2Congenital Hyperinsulinism Market Report Introduction 先天性高胰岛素血症市场报告简介3 3Executive Summary of Congenital Hyperinsulinism 先天性高胰岛素血症执行摘要4 4Key Events 关键事件5 五Epidemiology and Market Forecast Methodology 流行病学与市场预测方法论6 六Congenital HyperinsulinismMarket Overview at a Glance 先天性高胰岛素血症市场概览一览6.1 6.1Market Share (%) Distribution by Therapies in 2025 2025年按疗法划分的市场份额（%）分布6.2 6.2Market Share (%) Distribution by Therapies in 2036 2036年按疗法划分的市场份额（%）分布7 7Disease Background and Overview of Congenital Hyperinsulinism 先天性高胰岛素血症的疾病背景与概述7.1 7.1Introduction 引言7.2 7.2Causes of Congenital Hyperinsulinism 先天性高胰岛素血症的病因7.3 7.3Signs and Symptoms of Congenital Hyperinsulinism 先天性高胰岛素血症的体征与症状7.4 7.4Pathogenesis of Congenital Hyperinsulinism 先天性高胰岛素血症的发病机制7.5 7.5Pathophysiology of Itch in Congenital HyperinsulinismSkin 先天性高胰岛素血症中瘙痒的病理生理学 皮肤7.6 7.6Classification of Congenital Hyperinsulinism 先天性高胰岛素血症的分类7.7 7.7Genetic Bases of Congenital Hyperinsulinism 先天性高胰岛素血症的遗传基础7.8 7.8Diagnosis of Congenital Hyperinsulinism 先天性高胰岛素血症的诊断8 8Treatment and Management of Congenital Hyperinsulinism 先天性高胰岛素血症的治疗与管理9 9Treatment Guidelines 治疗指南10 10Epidemiology and Patient Population of Congenital Hyperinsulinism 先天性高胰岛素血症的流行病学与患者人群10.1 10.1Key Findings 主要发现10.2 10.2Assumption and Rationale 假设与依据10.3 10.3Total Diagnosed Prevalent Cases of Congenital Hyperinsulinism in the 7MM 七大主要市场（7MM）中先天性高胰岛素血症的确诊患病总病例数10.4 10.4The United States 美国10.4.1 10.4.1Total Diagnosed Prevalent Cases of Congenital Hyperinsulinism in the United States 美国先天性高胰岛素血症的确诊患病总病例数10.4.2 10.4.2Type-specific Diagnosed Prevalent Cases of Congenital Hyperinsulinism based on Histological Presentation in the United States 美国基于组织学表现的先天性高胰岛素血症各类型确诊患病病例10.4.3 10.4.3Mutation-specific Diagnosed Prevalent Cases of Congenital Hyperinsulinism in the United States 美国按突变类型分类的先天性高胰岛素血症确诊现患病例10.4.4 10.4.4Total Treated Cases of Congenital Hyperinsulinism in the United States 美国先天性高胰岛素血症的总治疗病例数10.5 10.5EU4 and the UK 欧盟四国与英国10.6 10.6Japan 日本11 十一Patient Journey of Congenital Hyperinsulinism 先天性高胰岛素血症患者诊疗历程12 十二Emerging Congenital Hyperinsulinism Drugs 新兴的先天性高胰岛素血症药物12.1 12.1Emerging Competitive Landscape of Congenital Hyperinsulinism 先天性高胰岛素血症新兴的竞争格局12.2 12.2ZEGALOGUE (dasiglucagon): Zealand Pharma ZEGALOGUE（达胰高血糖素）：Zealand Pharma12.2.1 12.2.1Product Description 产品描述12.2.2 12.2.2Other Developmental Activities 其他发展活动12.2.3 12.2.3Clinical Developmental Activities 临床开发活动12.2.3.1 12.2.3.1Clinical Trial Information 临床试验信息12.2.4 12.2.4Safety and Efficacy 安全性和有效性12.2.5 12.2.5Analyst's View 分析师观点12.3 12.3Ersodetug (RZ358): Rezolute Ersodetug（RZ358）：RezoluteList to be continued in the report… 列表中将在报告中继续…13 13Congenital Hyperinsulinism Market: 7MM Analysis 先天性高胰岛素血症市场：七国市场分析13.1 13.1Key Findings 主要发现13.2 13.2Congenital Hyperinsulinism Market Outlook 先天性高胰岛素血症市场前景展望13.3 13.3Key Congenital Hyperinsulinism Market Forecast Assumptions 先天性高胰岛素血症市场预测的关键假设13.4 13.4Conjoint Analysis 联合分析13.5 13.5Total Market Size of Congenital Hyperinsulinism in the 7MM 七大主要市场（7MM）先天性高胰岛素血症的总体市场规模13.6 13.6United States Congenital Hyperinsulinism Market Size 美国先天性高胰岛素血症市场规模13.6.1 13.6.1Total Market Size of Congenital Hyperinsulinism in the United States 美国先天性高胰岛素血症的总体市场规模13.6.2 13.6.2Market Size of Congenital Hyperinsulinism by Therapies in the United States 美国按疗法划分的先天性高胰岛素血症市场规模13.7 13.7EU4 and the UK Congenital Hyperinsulinism Market Size 欧盟四国及英国先天性高胰岛素血症市场规模13.8 13.8Japan Congenital Hyperinsulinism Market Size 日本先天性高胰岛素血症市场规模14 十四Unmet Needs of Congenital Hyperinsulinism 先天性高胰岛素血症的未满足需求15 十五SWOT Analysis of Congenital Hyperinsulinism 先天性高胰岛素血症的SWOT分析16 十六KOL Views of Congenital Hyperinsulinism 先天性高胰岛素血症的关键意见领袖观点17 17Market Access and Reimbursement of Congenital Hyperinsulinism 先天性高胰岛素血症的市场准入与报销17.1 17.1United States 美国17.2 17.2EU4 and the UK 欧盟四国与英国17.3 17.3Japan 日本17.4 17.4Congenital Hyperinsulinism: Market Access and Reimbursement 先天性高胰岛素血症：市场准入与报销18 十八Bibliography 参考文献19 十九Congenital Hyperinsulinism Market Report Methodology 先天性高胰岛素血症市场报告方法论Related Reports 相关报告Congenital Hyperinsulinism Clinical Trial Analysis 先天性高胰岛素血症临床试验分析Congenital Hyperinsulinism 先天性高胰岛素血症Pipeline Insight 管道洞察– –2026 2026report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key congenital hyperinsulinism companies, including 本报告提供关于管线格局、管线药物概况（包括临床和非临床阶段产品）以及先天性高胰岛素血症领域关键企业的全面洞察，包括Zealand Pharma, Rezolute, Amylyx Pharmaceuticals, Hanmi Pharmaceutical, Zealand Pharma、Rezolute、Amylyx Pharmaceuticals、韩美制药，and others. 等等。Post-bariatric Hypoglycemia Market 减重术后低血糖市场Post-bariatric Hypoglycemia Market Insights, Epidemiology, and Market Forecast – 2036 减重术后低血糖市场洞察、流行病学及市场预测 – 2036report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key post-bariatric hypoglycemia companies, including 本报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和关键的减肥术后低血糖症企业，包括Amylyx Pharmaceuticals, Vogenx, Recordati Group, MBX Biosciences, Confo Therapeutics, Gubra, Hanmi, Amylyx Pharmaceuticals、Vogenix、Recordati集团、MBX Biosciences、Confo Therapeutics、Gubra、韩美制药and others. 以及其他。Hyperinsulinemic Hypoglycemia 高胰岛素性低血糖症Market 市场Hyperinsulinemic Hypoglycemia 高胰岛素性低血糖症Market Insights, Epidemiology, and Market Forecast 市场洞察、流行病学及市场预测– –2036 2036report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hyperinsulinemic hypoglycemia companies, including 本报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和关键的高胰岛素血症性低血糖症企业，包括Eli Lilly and Company, Novo Nordisk A/S, Sanofi S.A., Aton Pharma, Inc. (Mallinckrodt Pharmaceuticals), Ipsen Pharma (IPSEN S.A.), Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Wockhardt Limited, Baxter International Inc., Sandoz International GmbH (Novartis AG), Fresenius Kabi AG, Mylan N.V., Accord Healthcare Ltd., Oramed Pharmaceuticals Inc.. 礼来公司、诺和诺德公司、赛诺菲公司、阿顿制药公司（马林克罗特制药）、益普生制药（益普生公司）、梯瓦制药工业有限公司、雷迪博士实验室有限公司、沃克哈特有限公司、百特国际有限公司、山德士国际有限公司（诺华公司）、费森尤斯卡比公司、迈兰公司、Accord Healthcare Ltd.、奥拉梅德制药公司。, ，and others. 以及其他。Severe Hypoglycemia Market 重度低血糖市场Severe Hypoglycemia Market Insights, Epidemiology, and Market Forecast – 2036 重度低血糖市场洞察、流行病学及市场预测——2036年report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key severe hypoglycemia companies, including 本报告深入解析了该疾病、历史及预测流行病学，以及市场趋势、市场驱动因素、市场壁垒和关键的重度低血糖症企业，包括Xeris Pharmaceuticals, Fresenius Kabi, Eli Lilly, Novo Nordisk, Amphastar Pharmaceuticals, Eiger BioPharmaceuticals, Zeal Pharma, Xeris Pharmaceuticals，Fresenius Kabi，Eli Lilly，Novo Nordisk，Amphastar Pharmaceuticals，Eiger BioPharmaceuticals，Zeal Pharma，and others. 以及其他。About 关于DelveInsight DelveInsightDelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve. DelveInsight 是一家领先的商业咨询和市场研究公司，专注于生命科学领域。它通过提供全面的端到端解决方案，帮助制药公司提升业绩。通过我们的订阅制平台 PharmDelve，您可以轻松获取所有医疗保健和制药市场研究报告。. 。Contact Us: 联系我们：Shruti Thakur 什鲁蒂·塔库尔[emailprotected] [email protected]+14699457679 +14699457679www.delveinsight.com www.delveinsight.comSOURCE DelveInsight Business Research, LLP 来源：DelveInsight 商业研究有限责任公司21 二十一% %more press release views with 更多新闻稿浏览量，通过Request a Demo 申请演示
